Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04406649 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Satsuma Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 482
- Enrollment target
NCT04406649 is a Phase 3 study that has completed, run by Satsuma Pharmaceuticals. The registered enrollment target is 482 participants.
The verdict
NCT04406649, a Phase 3 study, has completed, sponsored by Satsuma Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 482 participants
- Enrollment target
Study Summary
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Interventions
- DRUG Dihydroergotamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 482 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2023-01-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04406649
The ClinicalTrials.gov registry entry for NCT04406649 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 482 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Satsuma Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dihydroergotamine is the first listed.
NCT04406649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04406649 about?
NCT04406649 is a clinical study titled "A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine". Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
What is the current status of trial NCT04406649?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 482 participants. The study started on 2020-09-14. Estimated completion is 2023-01-16.
What interventions are being tested in trial NCT04406649?
The interventions under investigation include: Dihydroergotamine (DRUG).
Who is sponsoring clinical trial NCT04406649?
This trial is sponsored by Satsuma Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.